NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma

Barbara Jeker(University of Bern), Thomas Pabst(University Hospital of Bern), J-M Luethi(Regionalspital Emmental), Axel Ruefer(Luzerner Kantonsspital), Stefan Farese(Solothurner Spitäler), Urban Novak(University of Bern), Katja Seipel(University of Bern), Gabriela M. Baerlocher(Terry Fox Research Institute), Behrouz Mansouri Taleghani(University of Bern), Daniel Betticher, Martin Bigler(Swiss Group For Clinical Cancer Research), Beatrice U. Mueller
Bone Marrow Transplantation
October 23, 2017
10.1038/bmt.2017.234
Cited by 11

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Mutations in <i>TERT,</i> the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia
|New England Journal of Medicine|2005|717
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
|Leukemia|2012|417
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
|Leukemia|2017|339